FR2944448B1 - Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. - Google Patents

Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.

Info

Publication number
FR2944448B1
FR2944448B1 FR0807438A FR0807438A FR2944448B1 FR 2944448 B1 FR2944448 B1 FR 2944448B1 FR 0807438 A FR0807438 A FR 0807438A FR 0807438 A FR0807438 A FR 0807438A FR 2944448 B1 FR2944448 B1 FR 2944448B1
Authority
FR
France
Prior art keywords
hydrofob
polysacharide
amphiphilic
alcohols
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0807438A
Other languages
English (en)
Other versions
FR2944448A1 (fr
Inventor
Olivier Soula
Gerard Soula
Remi Soula
Martin Gaudier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0807438A priority Critical patent/FR2944448B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to JP2011542918A priority patent/JP2012513456A/ja
Priority to EP09805833A priority patent/EP2381960A1/fr
Priority to PCT/IB2009/007899 priority patent/WO2010073119A1/fr
Priority to US12/654,552 priority patent/US20110014189A1/en
Priority to CN2009801559091A priority patent/CN102300586A/zh
Priority to CA2748069A priority patent/CA2748069A1/fr
Priority to AU2009332642A priority patent/AU2009332642A1/en
Publication of FR2944448A1 publication Critical patent/FR2944448A1/fr
Priority to IL213682A priority patent/IL213682A0/en
Application granted granted Critical
Publication of FR2944448B1 publication Critical patent/FR2944448B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
FR0807438A 2008-12-23 2008-12-23 Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. Expired - Fee Related FR2944448B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0807438A FR2944448B1 (fr) 2008-12-23 2008-12-23 Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP09805833A EP2381960A1 (fr) 2008-12-23 2009-12-23 Composition pharmaceutique stable comprenant au moins un anticorps monoclonal et au moins un polysaccharide amphiphile comprenant des substituants hydrophobes
PCT/IB2009/007899 WO2010073119A1 (fr) 2008-12-23 2009-12-23 Composition pharmaceutique stable comprenant au moins un anticorps monoclonal et au moins un polysaccharide amphiphile comprenant des substituants hydrophobes
US12/654,552 US20110014189A1 (en) 2008-12-23 2009-12-23 Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents
JP2011542918A JP2012513456A (ja) 2008-12-23 2009-12-23 少なくとも１種のモノクローナル抗体及び疎水性置換基を有する少なくとも１種の両親媒性多糖類を含有する安定な医薬組成物
CN2009801559091A CN102300586A (zh) 2008-12-23 2009-12-23 稳定的药物组合物，其含有至少一种单克隆抗体和至少一种包含疏水性取代基的两亲性多糖
CA2748069A CA2748069A1 (fr) 2008-12-23 2009-12-23 Composition pharmaceutique stable comprenant au moins un anticorps monoclonal et au moins un polysaccharide amphiphile comprenant des substituants hydrophobes
AU2009332642A AU2009332642A1 (en) 2008-12-23 2009-12-23 Stable pharmaceutical composition containing at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents
IL213682A IL213682A0 (en) 2008-12-23 2011-06-21 Stable pharmaceutical composition containing at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0807438A FR2944448B1 (fr) 2008-12-23 2008-12-23 Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.

Publications (2)

Publication Number Publication Date
FR2944448A1 FR2944448A1 (fr) 2010-10-22
FR2944448B1 true FR2944448B1 (fr) 2012-01-13

Family

ID=40735852

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0807438A Expired - Fee Related FR2944448B1 (fr) 2008-12-23 2008-12-23 Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.

Country Status (9)

Country Link
US (1) US20110014189A1 (fr)
EP (1) EP2381960A1 (fr)
JP (1) JP2012513456A (fr)
CN (1) CN102300586A (fr)
AU (1) AU2009332642A1 (fr)
CA (1) CA2748069A1 (fr)
FR (1) FR2944448B1 (fr)
IL (1) IL213682A0 (fr)
WO (1) WO2010073119A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3300717T3 (pl) * 2009-06-29 2021-04-19 Inolex Investment Corporation Kationowe emulgatory niepochodzące z procesów petrochemicznych, które są zobojętnionymi estrami aminokwasów oraz kompozycje i sposoby
FR2956116A1 (fr) * 2010-02-09 2011-08-12 Adocia Complexes polysaccharide/bmp-7 solubles a ph physiologique
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2646468B1 (fr) 2010-12-01 2018-07-25 AlderBio Holdings LLC Compositions anti-ngf et leur utilisation
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
MX2014001190A (es) * 2011-08-10 2014-05-12 Adocia Solucion inyectable de al menos insulina basal.
GB201116116D0 (en) * 2011-09-19 2011-11-02 Univ York Cell differentiation
SG10202112306UA (en) * 2012-11-13 2021-12-30 Adocia Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
AU2013346624B2 (en) 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) * 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
JP2016523125A (ja) 2013-05-30 2016-08-08 グラハム エイチ． クリーシー 局所神経性刺激
WO2015038884A2 (fr) 2013-09-13 2015-03-19 Genentech, Inc. Compositions et méthodes de détection et de quantification d'une protéine cellulaire hôte dans des lignées cellulaires et polypeptides recombinés
CA2921999C (fr) 2013-09-13 2023-03-21 Genentech, Inc. Methodes et compositions comprenant un anticorps anti-il-13 et une phospholipase b-like 2 de hamster residuelle
AR098155A1 (es) 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
SG10202108879SA (en) * 2014-02-10 2021-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
AU2015218631A1 (en) 2014-02-21 2016-08-11 Genentech, Inc. Anti-IL-13/IL-17 bispecific antibodies and uses thereof
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
EP3851111A1 (fr) * 2014-07-10 2021-07-21 Biothera, Inc. Bêta-glucane en combinaison avec des agents anticancéreux affectant le microenvironnement de la tumeur
GB201419794D0 (en) * 2014-11-06 2014-12-24 Neo Innova Healthcare Ltd Insect repellents
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
KR20170127011A (ko) 2015-03-16 2017-11-20 제넨테크, 인크. Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도
EP3341409A1 (fr) 2015-08-24 2018-07-04 Glaxosmithkline Intellectual Property (No. 2) Limited Compositions biopharmaceutiques
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
FR3045834B1 (fr) 2015-12-21 2021-03-05 Biomerieux Sa Diluant de reactifs pour immunoessai
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
JP2019527192A (ja) 2016-05-31 2019-09-26 カーディオバックス リミテッド ライアビリティ カンパニー 全身性エリテマトーデスの診断及び治療方法
AU2017330405B2 (en) 2016-09-23 2024-02-01 Genentech, Inc. Uses of IL-13 antagonists for treating atopic dermatitis
WO2018106644A1 (fr) * 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc Conjugués d'anticorps de trastuzumab ss-1,6-glucane
JP7254350B2 (ja) 2016-12-07 2023-04-10 イネイト バイオセラピューティクス， エルエルシー β－１，６－グルカン治療用抗体コンジュゲート
CN111601636A (zh) 2017-11-07 2020-08-28 Oab神经电疗科技公司 具有自适应电路的非侵入性神经激活器
WO2019147824A1 (fr) 2018-01-26 2019-08-01 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de pde4
CA3226165A1 (fr) 2018-02-09 2019-08-15 Genentech, Inc. Procedes therapeutiques et de diagnostic pour des maladies inflammatoires mediees par des mastocytes
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
EP3810085A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal par un inhibiteur de l'intégrine
EP3810094A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un jak ou un autre inhibiteur de kinase
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246313A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
EP3810268A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-12/il-23
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
JP7266108B2 (ja) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
KR20220025834A (ko) 2019-06-26 2022-03-03 뉴로스팀 테크놀로지스 엘엘씨 적응적 회로를 갖는 비침습적 신경 활성화기
EP4017580A4 (fr) 2019-12-16 2023-09-06 Neurostim Technologies LLC Activateur nerveux non invasif à distribution de charge amplifiée
CN111171174B (zh) * 2020-01-14 2022-02-01 上海图珐医药科技有限公司 葡聚糖衍生物及其制备方法和用于制备药剂的附加剂
CN118076636A (zh) 2021-09-15 2024-05-24 德米拉公司 Il-13抑制剂用于治疗结节性痒疹

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) * 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
US2954372A (en) * 1956-11-16 1960-09-27 Leo J Novak Higher fatty acid esters of dextran
US4826818A (en) 1983-10-26 1989-05-02 Kanebo Ltd. Proteinaceous emulsifier, process for preparing same and emulsion type cosmetic compositions containing same
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
US6656481B1 (en) * 1996-09-06 2003-12-02 Mitsubishi Chemical Corporation Vaccinal preparations
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
KR20110091822A (ko) * 2002-02-14 2011-08-12 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
CN1401389A (zh) * 2002-10-17 2003-03-12 北京绿竹生物技术有限责任公司 新的乙型肝炎疫苗制剂
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2914305B1 (fr) * 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
CN101466404A (zh) * 2006-06-14 2009-06-24 埃姆克隆系统股份有限公司 抗-egfr抗体的冻干制剂
BRPI0809674A2 (pt) 2007-03-30 2014-10-07 Medimmune Llc Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5

Also Published As

Publication number Publication date
CA2748069A1 (fr) 2010-07-01
WO2010073119A1 (fr) 2010-07-01
EP2381960A1 (fr) 2011-11-02
IL213682A0 (en) 2011-07-31
US20110014189A1 (en) 2011-01-20
FR2944448A1 (fr) 2010-10-22
CN102300586A (zh) 2011-12-28
AU2009332642A1 (en) 2011-07-07
JP2012513456A (ja) 2012-06-14

Similar Documents

Publication Publication Date Title
FR2944448B1 (fr) Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
MEP18208A (en) Immune response modifier foam formulations
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA40571B1 (fr) Composition comprenant un melange d'extraits vegetaux ou un melange de molecules contenues dans ces vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
UY32649A (es) "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato"
FR2894827B1 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation,et leurs utilisations
FR2912310B1 (fr) Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.
SMT201400076B (it) Formulazioni farmaceutiche contro l'uso improprio di medicinali
FR2892923B1 (fr) Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
MA29090B1 (fr) Composes inhibiteurs de la phosphorylase du glycogene et compositions pharmaceutiques les comprenant
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
FR2953135B1 (fr) Extrait de graines d'acacia macrostachya et compositions cosmetiques, pharmaceutiques, dermatologiques, nutraceutiques ou alimentaires le comprenant
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
MA33220B1 (fr) Composition pharmaceutique a proprietes anti-inflammatoires
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
MA34387B1 (fr) Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté
WO2010021607A3 (fr) Préparation pharmaceutique
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
BR112014023952A2 (pt) formulações de agentes de ligação à base de igg4 estáveis
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
FR2888748B1 (fr) Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
FR2920774B1 (fr) Nouveaux derives de n-phenul acatamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contentant
MA55033A (fr) Formulation d'anticorps thérapeutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130830